Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 5, 1996, Pages 955-963

  Teng, Renli ^a   Liston, Theodore E ^a   Harris, Stephen C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG URINE LEVEL; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HEADACHE; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; SLEEP STAGES;

EID: 0029941236     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.5.955     Document Type: Article

References (12)

1. Boudinot, F. D. & Jusko, W. J. (1984), Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. Journal of Pharmaceutical Science 73, 774-80.
2. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
3. Fitton, A. (1992). The quinolones: an overview of their pharmacology. Clinical Pharmacokinetics 22, Suppl. 1, 1-11.
4. Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd edn. Marcel Dekker, New York.
5. Girard, D., Bighty, K. E. & Gootz, T. D. (1993). CP-99,219, a novel 7-(3-azabicyclo [3.1.0] hexyl)naphthyridon: pharmacokinetics in animals. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993. Abstract 1511, p. 138. American Society for Microbiology, Washington, DC.
6. Gooding, B. B. & Johns, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel 7-azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
7. Gootz, T. D., Bighty, K. E., Anderson, M. R., Schmieder, B. J., Haskell, S. L., Sutcliffe, J. A. et al. (1994). In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0.]hexyl) naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
8. Neu, H. C. & Chin, N. X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
9. Teng, R., Tensfeldt, T. G., Liston, T. E. & Foulds, G. (1996). Determination of trovafloxacin, a new oral quinolone antibiotic, in biological samples by reverse-phase high performance liquid chromatography. Journal of Chromatography B, 675, 53-59.
10. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995a). Pharmacokinetics and safety of CP-99,219, a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
11. Teng, R., Khosla, N. B., Renouf, D. N., Girard, G., Silber, B. M., Foulds, G. et al. (1993). Pharmacokinetics of CP-99,219, a new oral quinolone antibiotic, in Sprague-Dawley rats, beagle dogs and cynomolgus monkeys. Pharmaceutical Research 10, S336.
12. Teng, R., Liston, T. E., Dogolo, L. C. & Harris, S. C. (1995b). Multiple dose pharmacokinetics and safety of CP-99,219, a new quinolone antibiotic, in healthy male volunteers. In Program and Abstracts of the Nineteen International Congress of Chemotherapy, Montreal, Canada. 1995. Abstract 5109, p. 445C. International Society of Chemotherapy.